PremiumThe FlyCastle Biosciences price target lowered to $40 from $44 at Scotiabank Castle Biosciences announces new data on DecisionDx-UM Castle supporting series of initiatives to raise awareness of skin cancer PremiumCompany AnnouncementsCastle Biosciences Reports Strong Q1 2025 Growth Castle Biosciences to acquire Capsulomics, terms undisclosed Castle Biosciences reports Q1 adjusted EPS (20c), consensus (7c) PremiumThe FlyCastle supports educational programs, initiatives for esophageal cancer Castle Biosciences announces publication of papers on DecisionDx-Melanoma test Castle Biosciences price target lowered to $30 from $37 at Guggenheim 
